Recombinant SARS-CoV-2 S1S2 ECD-His Protein (HEK293)

Product Description: Recombinant Antigen

Recombinant SARS-CoV-2 S1+S2 ECD (S-ECD) Protein with His tag (Wild type, pre-fusion state plus post-fusion state) is produced using the HEK293 cell expression system. The target protein corresponds to amino acid sequence Val11-Gln1208 of the SARS-CoV-2 (2019-nCoV) S1+S2 ECD (S-ECD) (Accession #YP_009724390.1), with a 6×His tag fused at the C-terminus.

Bioactivity Measured by its binding ability in functional ELISA. Immobilized Recombinant SARS-CoV-2 Spike S1+S2 ECD-His at 2 μg/mL (100 μL/well) binds Recombinant Human ACE2 with a linear detection range of 0.15–9.92 ng/mL.

Endotoxin Level Less than 0.1 EU/μg as determined by the LAL method.

Formulation Supplied as a sterile-filtered solution at 0.22 μm in PBS, pH 7.4. Custom product forms or formulations available upon request.

Calculated Molecular Weight 133.8 kDa

Background The spike (S) glycoprotein of coronavirus mediates viral entry by binding to the host cell receptor angiotensin-converting enzyme 2 (ACE2). A specific receptor-binding domain (RBD) within the S protein facilitates this interaction. The S protein is a critical antigen for eliciting neutralizing antibodies and T-cell responses, contributing significantly to protective immunity against infection.

Product Information Synonyms: CoV spike protein; 2019-nCoV; nCoV spike protein; coronavirus spike protein; S glycoprotein; COVID-19; S protein; Spike glycoprotein Expression Host: HEK293 cells

Applications Suitable for use in immunoassays, antibody development, vaccine research, and structural studies related to SARS-CoV-2. Ideal for applications requiring authentic spike protein conformational states (pre-fusion and post-fusion).